Rapport Therapeutics Executive Sells Small Stake as RAP-219 Development Accelerates
Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares under a pre-arranged 10b5-1 plan, while the company prepares to present Phase 2a data and accelerate a pivotal Phase 3 program for RAP-219. Multiple brokerages have maintained or raised price targets following the company’s fiscal 2025 results and program updates…